A Professional Networking Site for Doctors & Medical Students Worldwide

New Medical News


New Medical News

Dear doctors .everyday we hear or read about new applications in diagnosis ,medical n surgical t/t ,so lets share n exchange these news.....

Location: WORLD
Members: 290
Latest Activity: Aug 6

Comment Wall


You need to be a member of New Medical News to add comments!

Comment by Dahl Domingo on December 24, 2013 at 1:35am

The 16 Most Expensive Substances In The World

see this------>Top 16 Expensive things

Comment by summaiya javed on December 23, 2013 at 11:17pm
Ohh! New thing
Comment by Noela on July 30, 2013 at 11:39am

Bydureon, The Once A Week Form Of Byetta by Injection.. It does NOT replace insulin.

Amylin, the drug company that developed Byetta, is currently working on a time-released version of Byetta, now called Bydureon, that would only need to be injected once a week. The newest report from Amylin shows that it outperforms it's rival, Januvia, but remains inline with Actos and Metformin when comparing A1C levels. The 26 week trial participants were not achieving good A1c control using diet and exercise alone and they were under no diabetes therapy. After 26 weeks, users of Bydureon showed a 1.5% reduction in their A1cs, compared to 1.2% from Januvia. Users of metformin and actos showed 1.5% and 1.6% reductions, respectively.


Bydureon is set up to be taken once weekly. This is a benefit when compared to Januvia, Actos, Metformin, and Byetta which are all taken more frequently. Convenience goes a long way towards helping improve management.

 Dapagliflozin will be released in Australia at the end of this year

ADA 2013: Dapagliflozin Update

Durability of Dapagliflozin vs. Glipizide as Add-On Therapies in T2DM Inadequately Controlled on Metformin: 4-Year Data

The efficacy, tolerability and safety of dapagliflozin was studied compared to glipizide over a period of 4 years. Dapagliflozin is a novel medication that is a highly selective inhibitor of SLGLT2 and reduces blood glucose independently of insulin by increasing excretion of glucose through the urine. In a randomized, double-blind, active controlled study, the researchers compared dapagliflozin to glipizide as add-on medications to metformin. The primary endpoints of focus were changes in HbA1c, weight and systolic blood pressure (SBP) at 52 weeks. Data was collected up to 208 weeks as part of the extension period. Safety and Tolerability were determined by the incidence of adverse events (side effects, hypoglycemia, UTI)....

After 52 weeks, dapagliflozin was reported to be non-inferior to glipizide regarding change in HbA1c. Dapagliflozin did show better sustained reduction of HbA1c compared to glipizide after 52 weeks and up to 208 weeks. Dapagliflozin showed sustained weight loss over 4 years whereas glipizide had shown sustained weight gain. The SBP was also found to be consistently lower in patients taking dapagliflozin. In regards to safety and tolerability, glipizide use resulted in 10 times the incidence of hypoglycemia during the first year compared to dapagliflozin. Genital infections and UTI were more frequent with the use of dapagliflozin.

Comment by mohammedalkhatib64 on January 20, 2013 at 10:25am
Thank u
Comment by parveen on October 8, 2012 at 7:13am

Scientists Uncover Genetic Link for Uterine Fibroids

THURSDAY, Oct. 4 (Health Day News) -- Researchers who discovered genetic risk factors linked to uteri fibroid in white women say their findings will lead to new screening and treatment methods for the condition.

Uterine fibroids are the most common type of pelvic tumour in women -- they occur in 75 percent of women of reproductive age -- and the leading cause of hysterectomy the United States. Uterine fibroids can lead to abnormal vaginal bleeding, infertility pelvic pain and pregnancy complications.

Researchers at Brigham and Women's Hospital in Boston analyzed genetic data from more than 7,000 white women and identified variations in three genes that are significantly associated with uterine fibroids.

One of these variations occurred in a gene called FASN, which encodes a protein called FAS (fatty acid synthase). Further investigation showed that FAS protein production was three times higher in uterine fibroid samples compared to normal tissue, according to the report published online Oct. 4 in the American Journal of Human Genetics.

Overproduction of FAS protein occurs in various types of tumors and is believed to be important for tumor cell survival, the study authors pointed out in a hospital news release.

"Our discovery foretells a path to personalized medicine for women who have a genetic basis for development of uterine fibroids," senior study author Cynthia Morton, director of the Center for Uterine Fibroids, said in the news release. "Identification of genetic risk factors may provide valuable insight into medical management

Comment by Dahl Domingo on September 25, 2012 at 9:22pm

Stem Cell Research – Man vs. God

Stem cells are the building blocks of life; they are the “Version 1.00″ of most cells of our body. All other cells (e.g. brain cells, blood cells, skin cells) are formed by the differentiation and maturation of these cells. The stem cells divide, mature and take on different functions based on the need. This is a process that occurs naturally when the embryo develops to a full term infant. These cells will continue to differentiate and integrate as a part of any other cell where it is transplanted.

Transplant these cells onto a site of injury, and the stage is set for potential healing and restoration of function.

How are these stem cells obtained?

Currently, the stem cells may be excavated from dead embryos, which were created solely “for the purpose of reproduction.” Adults also have a small percentage of stem cells in their bodies; these are found in the blood, in bone marrow, the brain, the liver and skin. There are 14 sites around the world that are recognized by the National Institute of Health Research as authorized suppliers of stem cells for research purposes. Research is currently being carried on to study the applicability of the stem cells in plastic surgery, in Parkinson’s disease and in spinal cord injury. People with spinal cord injuries may currently undergo the procedure of stem cell implantation in China or Portugal. There have been anecdotal reports of some functional gains after this surgery, but no published literature demonstrates significant improvement in independence.

Stem Cell research

Comment by S.UMA DEVI on April 3, 2012 at 7:12pm



Comment by S.UMA DEVI on April 3, 2012 at 5:51pm
Comment by S.UMA DEVI on September 24, 2011 at 8:02pm

From Medscape Medical News
EMA: Restrict Terpenoid-Containing Suppositories in Children
Jim Kling

September 23, 2011 — The European Medicines Agency has changed its recommendations for suppositories that contain terpenic derivatives. It now says that they should not be used in children younger than 30 months or in children who have experienced febrile convulsion, epilepsy, or recent anorectal lesions.
Terpenic derivatives include turpentine, camphor, cineole, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needle, and eucalyptus. They are commonly used to treat mild bronchial disorders, especially coughs.
The decision follows a review by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) that identified potential risks of terpenic derivatives. Among infants and small children, convulsions were a particular concern, along with other neurological disorders. The agents can also cause precancerous anorectal lesions, leading to the recommendation that children who have a recent history of such lesions should not receive these agents.
The CHMP review was prompted by the French medicines agency, which was particularly concerned about the potential for serious neurological adverse effects. The French agency carried out a risk–benefit assessment, which the CHMP considered in addition to information obtained from the manufacturers and marketers of suppositories that include terpenic derivatives.
Suppositories with terpenic derivatives are currently marketed in Belgium, France, Luxembourg, Finland, Italy, Portugal, and Spain.

Comment by S.UMA DEVI on September 4, 2011 at 8:12pm




Members (290)



  • Add Medical Images
  • View All


© 2018   Doctors Hangout | About DH   Powered by

Contact US  |  Report an Issue  |  Terms of Service